June 5 (Reuters) - Quark Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, on Tuesday filed with U.S. regulators to sell 5 million shares in an initial public offering at an estimated price of $12 to $14 a share.
June 5 (Reuters) - Quark Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, on Tuesday filed with U.S. regulators to sell 5 million shares in an initial public offering at an estimated price of $12 to $14 a share.
